Prognostic and Predictive Markers in Gynecological Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (1 March 2026) | Viewed by 562
Special Issue Editor
Special Issue Information
Dear Colleagues,
Recent advances have led to improvements in the recognition and molecular characterization of tumours of the female genital tract, with the landscape of therapeutic options extending beyond the limited traditional management options. An expanded selection of treatments, including new medications, has been approved, often with companion diagnostic tests. Biomarkers are used for diagnosis, risk stratification, management options, and for the monitoring of progression and recurrence. When advanced treatment options are available, the assessment of biomarkers in gynecological malignancies becomes integral to pathologic assessment, contributing to the growing need for resources and expertise.
For this Special Issue of Cancers, we welcome original and review papers that discuss recent advances in biomarkers relating to gynecological cancer. We are especially keen on papers that provide insight into new and original research methodologies, improved early detection and monitoring strategies, and original treatment approaches. Cancers is a journal focusing on different aspects of oncological care in all tumour types, and this Special Issue is aimed at growing the literature around the topic of biomarkers, which are instrumental to the development of personalized medicine and of healthcare broadly, and to the creation of a cancer-free future.
I look forward to receiving your contributions.
Sincerely,
Dr. Anna Plotkin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarker
- gynecological cancer
- management
- prognostic marker
- predictive marker
- personalized medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
